

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

GENOME THERAPEUTICS CORP

Form 8-K

August 09, 2001

1

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report : August 8, 2001

Commission File No: 0-10824

GENOME THERAPEUTICS CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

MASSACHUSETTS

0-10824

04-2297484

(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

(COMMISSION FILE NUMBER)

(I.R.S. EMPLOYER
IDENTIFICATION NO.)

100 BEAVER STREET, WALTHAM, MASSACHUSETTS 02453

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

Registrant's telephone number: (781) 398-2300

Not Applicable

Former name or former address, if changed since last report)

2

ITEM 8. CHANGE IN FISCAL YEAR

On July 24, 2001 the Board of Directors of Genome Therapeutics Corp. ("Genome") approved a change of Genome's fiscal year end from August 31 to December 31, as of the fiscal year ended December 31, 2000. A transition report on Form 10-Q covering the transition period from September 1, 2000 through December 31, 2000, will be filed with the Securities and Exchange Commission by no later than September 7, 2001; this filing will include financial statements restated to provide financial information for the four months ended December 31, 2000 and 1999.

3

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP

By: /s/ Stephen Cohen

Stephen Cohen,
Senior Vice President - Finance
and Chief Financial Officer

Date: August 8, 2001